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South Africa has a heavy burden of tuberculosis (TB); an
incidence of 526 cases per 100 000 of the population makes it
one of the highest in the world.1 Along with other severely
affected countries in eastern and southern Africa, there is a
significant degree of coinfection with HIV and Mycobacterium
tuberculosis (MTB). In the World Health Organisation (WHO)
African Region, 31% of adults aged 15 - 49 years with TB are
also HIV-positive.2 In South Africa, the cure rate for new smear-
positive cases is 54%, and 63% of patients successfully
complete their treatment regimen;3 these figures are well below
WHO targets. They should be viewed within the context of
rising caseloads and a projected fall in public sector health care
investment, after a period of substantial growth from 1993 to
1998.4,5 Although the incidence of multiple-drug-resistant TB in
South Africa is currently low,6 HIV has been associated with
epidemic outbreaks of multidrug-resistant strains.2 There is an
emerging view that the efficacy of TB control programmes,
particularly with regard to adherence, could be increased if
patients' beliefs about their infection were taken into account.7
Traditional healers are widely consulted in rural areas of South
Africa and have been successfully recruited as short-course
DOTS (directly observed therapy short-course) programme
supervisors.8
There may be other aspects of traditional medicine that
could supplement conventional treatments and impact on
adherence and cure rates. For example, Honeybush tea, an
infusion of leaves and stems of Cyclopia intermedia, indigenous
to South Africa and rich in flavonoids, has been used for
restorative purposes, such as soothing coughs and alleviating
bronchial complaints including TB, pneumonia and catarrh.9
We have been investigating another herbal concoction with a
long history of use in South African native medicine. Extracts
of the roots of two species of indigenous geraniums,
Pelargonium sidoides and P. reniforme, known locally as
umckaloabo, were introduced into Europe as a ‘vegetable
germicide’ and are still widely available, particularly in
Germany, where they are used as over-the-counter
preparations for treatment of various respiratory ailments.10
‘Stevens’ cure’
In 1897 Charles Stevens, a young mechanic from Birmingham,
UK, fell ill with pulmonary TB and was sent by his doctor to
South Africa to optimise his chances of recovery.11 A fellow
sufferer who claimed to have been cured of consumption
directed him to a traditional healer, Mike Kijitse, who
administered a preparation of the roots. Stevens persevered
with the extracts and 3 months later felt well. Upon returning
to England he was pronounced free of TB.12 He later served in
the Boer War and then stayed in South Africa to establish a
company to sell umckaloabo, which he obtained from Kijitse.12
Stevens promoted his business by writing to doctors in South
Africa and England in praise of the anti-TB properties of
umckaloabo. Having been fined for unauthorised medical
practice, Stevens returned to England in 1907 and set up an
establishment in Wimbledon to prepare and sell the remedy. In
1909, the British Medical Association (BMA), in a campaign
against ‘secret remedies’, accused Stevens of quackery and
fraud.13 His income suffered as a result and he brought an
action for libel against the BMA, which was heard in London in
1912. The jury could not agree on a verdict and a second trial
took place in the summer of 1914. Despite the support of a
number of expert witnesses who gave evidence in favour of
Stevens, the jury found in favour of the BMA and Stevens was
ordered to pay substantial costs.12
At the first trial, eight physicians who had used ‘Stevens’
Consumption Cure’ offered clinical evidence in support of
Stevens's contention that his extracts were efficacious. The
majority were convinced that many of the patients they had
treated, totalling around 130, had obtained significant benefit
from the remedy. These doctors were ill at ease in finding
themselves in conflict with their professional body and did not
appear at the second trial. In 1920, a Swiss physician, Dr
Adrien Sechehaye, heard of Stevens' Cure and decided to use
it. He subsequently published a large body of evidence relating
to its efficacy.14,15 The first patient he treated was a young girl
with severe TB who recovered after taking umckaloabo powder
in a cup of water twice daily for 3 months. Sechehaye was
impressed with the fact that fever and pain abated within days
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of commencement of treatment. During convalescence the
patient stopped taking the extract and iliac cavity pain
returned along with loss of appetite and general lassitude.
When treatment was recommenced, she again improved,
continued with the medication and this time recovered fully.11
Periods of improvement therefore coincided exactly with those
in which umckaloabo was administered. This prompted
Sechehaye to administer umckaloabo to around 800 patients over
the next 9 years, to present many of these cases to the Medical
Society of Geneva14 and to commission laboratory
investigations of the antibacterial action of umckaloabo.11
Sechehaye published detailed case histories of 64 patients
who had received extracts over the period 1920 - 1929,11 paying
particular attention to the accuracy of diagnosis, the possibility
of spontaneous remission and the length of time patients
remained symptom-free. In the large majority of patients he
established the presence of TB through radiology, skin
reactivity, isolation of MTB and the application of Koch's
postulates. In most cases the disease was of a progressive
nature, and was persistent. Many patients had a marked
tendency to relapse with aggravated symptoms, and showed
no tendency to spontaneous recovery. Patients were observed
for up to 9 years after cessation of treatment with umckaloabo.
In evaluating his case studies Sechehaye set aside 14 cases that
he considered too recent, 2 who died, 1 whose recovery he
ascribed to the Leysin sanatorium and 4 who disappeared. Of
the remaining 43, 29 remained healthy. He ascribed some of the
treatment failures to ‘insufficient continuance of the treatment’,
‘indiscipline of the patient’, unfavourable material and moral
conditions’, ‘concomitant illnesses’ and ‘refractory cases’. Other
less detailed case histories were published by Sechehaye.14,15 He
applied the same exacting criteria, and a large number of
apparent cures were evident. During this period Stevens
continued to send extracts to subscribers and some of the
outcomes were described in a book published in 1931.16
Conversations with patients, or their relatives, who were
treated with umckaloabo supplied by Stevens support the view
that the extracts were efficacious (TB patients continued to be
treated with umckaloabo until the late 1950s).17
How it worked
Mainstream medical opinion at the time dismissed this work
because the term umckaloabo had not been recorded in any
recognised pharmacopoeia or contemporary book on
pharmacy,12 so the precise botanical nature of the remedy was
in doubt for many years. Subsequent analysis indicated that
the roots were obtained from species of the order Geraniaceae.18
Phytochemical studies of P. sidoides and P. reniforme roots have
revealed the presence of a large number of secondary
metabolites, including coumarins, flavonoids, phenolic acid
derivatives, phytosterols and tannins.19 Constituents of both
species show antibacterial activity against Gram-positive and
Gram-negative isolates.20 In the 1920s Sechehaye commissioned
experiments in which MTB was grown on potato slices soaked
in extract, with no noticeable effects on either growth or
viability.11 He cogently argued that indirect, macrophage-
stimulating effects against the intracellular pathogen were most
likely to explain any clinical efficacy. More recently, crude
extracts have been tested against MTB by the Tuberculosis
Antimicrobial Acquisition and Coordinating Facility, Alabama
and showed some activity, with minimum inhibitory
concentrations (MICs) typically around 12.5 g/ml.19 We are
systematically searching for compounds in roots with
antimycobacterial activity and with the capacity to increase
uptake and killing of mycobacteria by macrophages.21 We
found that antimycobacterial activity was restricted to extracts
obtained with the apolar solvent n-hexane and gas
chromatographic and spectroscopic analysis enabled us to
identify mono- and diunsaturated fatty acids with
antimycobacterial activity. The most potent were oleic acid and
linoleic acid with MICs about 2 g/ml.21
We are now searching for compounds with the capacity to
stimulate the uptake of MTB by macrophages and other
phagocytic cells of the immune system. Our goal is to define
the full repertoire of bioactive components of umckaloabo and to
reconstitute and enhance the antimycobacterial activities of the
concoction. Stevens experienced vomiting after drinking the
extract provided by Kijitse, probably root bark boiled in goat's
milk,11 but the standard formulation he provided to his
customers (0.75 g umckaloabo powder made from an infusion
with hot water, taken twice daily11) was usually well tolerated.11
The removal of inactive, often insoluble,11 components should
increase pharmaceutical acceptability. Such modified, enhanced
formulations are likely to be culturally acceptable in sub-
Saharan Africa; the plants are indigenous to the region and if
proven efficacious there is no reason why formulations could
not be prepared locally for local markets and form an effective
supplement to conventional anti-TB therapy.
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